Business Description
Neurocrine Biosciences Inc
NAICS : 325414
SIC : 2836
ISIN : BRN1BIBDR009
Share Class Description:
BSP:N1BI34: BRDRTotal Employee Number:
2,500Compare
Compare
Traded in other countries / regions
NBIX.USA0K6R.UKN1BI34.BrazilNB3.Germany1NBIX.ItalyNBIX.Mexico IPO Date
2020-10-13Description
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.97 | |||||
Equity-to-Asset | 0.69 | |||||
Debt-to-Equity | 0.11 | |||||
Debt-to-EBITDA | 0.46 | |||||
Interest Coverage | 278 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 7.27 | |||||
Beneish M-Score | -2.1 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 22.8 | |||||
3-Year EBITDA Growth Rate | 34.5 | |||||
3-Year EPS without NRI Growth Rate | 22.6 | |||||
3-Year FCF Growth Rate | 30.8 | |||||
3-Year Book Growth Rate | 22.5 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 40.74 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 20.66 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 33.43 | |||||
9-Day RSI | 28.5 | |||||
14-Day RSI | 29.82 | |||||
3-1 Month Momentum % | 2.09 | |||||
6-1 Month Momentum % | 27.51 | |||||
12-1 Month Momentum % | 14.3 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.87 | |||||
Quick Ratio | 1.75 | |||||
Cash Ratio | 0.45 | |||||
Days Inventory | 387.24 | |||||
Days Sales Outstanding | 79.31 | |||||
Days Payable | 629.33 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.2 | |||||
Shareholder Yield % | 0.33 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 97.97 | |||||
Operating Margin % | 23.9 | |||||
Net Margin % | 20.91 | |||||
EBITDA Margin % | 25.66 | |||||
FCF Margin % | 26.11 | |||||
OCF Margin % | 26.92 | |||||
ROE % | 21.98 | |||||
ROA % | 15.3 | |||||
ROIC % | 18.75 | |||||
3-Year ROIIC % | 16.56 | |||||
ROC (Joel Greenblatt) % | 93.74 | |||||
ROCE % | 21.07 | |||||
Years of Profitability over Past 10-Year | 8 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 22.82 | |||||
Forward PE Ratio | 15.41 | |||||
PE Ratio without NRI | 18.66 | |||||
Shiller PE Ratio | 79.68 | |||||
Price-to-Owner-Earnings | 22.84 | |||||
PEG Ratio | 0.45 | |||||
PS Ratio | 4.78 | |||||
PB Ratio | 4.28 | |||||
Price-to-Tangible-Book | 16.34 | |||||
Price-to-Free-Cash-Flow | 18.52 | |||||
Price-to-Operating-Cash-Flow | 17.94 | |||||
EV-to-EBIT | 19.35 | |||||
EV-to-Forward-EBIT | 11.85 | |||||
EV-to-EBITDA | 18.29 | |||||
EV-to-Forward-EBITDA | 10.91 | |||||
EV-to-Revenue | 4.69 | |||||
EV-to-Forward-Revenue | 3.54 | |||||
EV-to-FCF | 18.19 | |||||
Price-to-GF-Value | 0.78 | |||||
Price-to-Projected-FCF | 1.74 | |||||
Price-to-Median-PS-Value | 0.55 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.75 | |||||
Price-to-Graham-Number | 3.68 | |||||
Earnings Yield (Greenblatt) % | 5.17 | |||||
FCF Yield % | 5.5 | |||||
Forward Rate of Return (Yacktman) % | 22.88 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Neurocrine Biosciences Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil R$) | 17,831.136 | ||
| EPS (TTM) (R$) | 1.806 | ||
| Beta | -0.5173 | ||
| 3-Year Sharpe Ratio | 0.43 | ||
| 3-Year Sortino Ratio | 0.65 | ||
| Volatility % | 35.43 | ||
| 14-Day RSI | 29.82 | ||
| 14-Day ATR (R$) | 0.228186 | ||
| 20-Day SMA (R$) | 40.716 | ||
| 12-1 Month Momentum % | 14.3 | ||
| 52-Week Range (R$) | 31.51 - 45.78 | ||
| Shares Outstanding (Mil) | 2,032.98 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Neurocrine Biosciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Neurocrine Biosciences Inc Stock Events
| Event | Date | Price (R$) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-11 16:30 | In 157 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-11 16:00 | In 157 days | ||
| Annual report for 2026 | 2027-02-11 | In 156 days | ||
| Third quarter earnings conference call for 2026 | 2026-10-28 16:30 | In 51 days | ||
| Third quarter earnings results for 2026 | 2026-10-28 16:00 | In 51 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-30 16:30 | 44.48 (+0.00%) | ||
| Second quarter earnings results for 2026 | 2026-07-30 | 44.48 (+0.00%) | ||
| Guidance call for 2026 | 2026-06-09 09:20 | 43.24 (+0.00%) | ||
| William Blair 46th Annual Growth Stock Conference | 2026-06-02 11:40 | 39.48 (+0.00%) | ||
| General meeting for 2026 | 2026-05-27 10:30 | 39.84 (+0.00%) |
Show
Entries
Neurocrine Biosciences Inc Frequently Asked Questions
What is Neurocrine Biosciences Inc(BSP:N1BI34)'s stock price today?
The current price of BSP:N1BI34 is R$40.04. The 52 week high of BSP:N1BI34 is R$45.78 and 52 week low is R$31.51.
When is next earnings date of Neurocrine Biosciences Inc(BSP:N1BI34)?
The next earnings date of Neurocrine Biosciences Inc(BSP:N1BI34) is 2026-10-28 Est..
Does Neurocrine Biosciences Inc(BSP:N1BI34) pay dividends? If so, how much?
Neurocrine Biosciences Inc(BSP:N1BI34) does not pay dividend.
Press Release
Articles on Neurocrine Biosciences Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers